Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
about
Combination of brinzolamide and brimonidine for glaucoma and ocular hypertension: critical appraisal and patient focusMedical Management of Glaucoma in the 21st Century from a Canadian PerspectiveGlaucoma: a review of adjunctive therapy and new management strategies.Efficacy and tolerability of a fixed-dose moxifloxacin - dexamethasone formulation for topical prophylaxis in LASIK: a comparative, double-masked clinical trial.An increased effect of pilocarpine on the pupil by application of the drug in oil.Safety and efficacy of fixed-combination travoprost/timolol in patients with open-angle glaucoma or ocular hypertension not controlled with timolol monotherapyDexamethasone diffusion across contact lenses is inhibited by Staphylococcus epidermidis biofilms in vitro.Fixed combination of bimatoprost and timolol in patients with primary open-angle glaucoma or ocular hypertension with inadequate IOP adjustmentEfficacy and tolerability of fixed-combination brinzolamide/timolol in Latin American patients with open-angle glaucoma or ocular hypertension previously on brimonidine/timolol fixed combination.Effects of rat anti-VEGF antibody in a rat model of corneal graft rejection by topical and subconjunctival routes.Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.Randomized trial of brinzolamide/brimonidine versus brinzolamide plus brimonidine for open-angle glaucoma or ocular hypertensionFixed combination of topical brimonidine 0.2% and timolol 0.5% for glaucoma and uncontrolled intraocular pressure.Efficacy and tolerability of a combined moxifloxacin/dexamethasone formulation for topical prophylaxis in phacoemulsification: an open-label single-arm clinical trial.Lyophilisates for drug delivery in ophthalmology: pharmacokinetics of fluorescein in the human anterior segment.A comparative bioavailability study of three conventional eye drops versus a single lyophilisate.A randomised trial of povidone-iodine to reduce visual impairment from corneal ulcers in rural Nepal.Efficacy and safety of fixed-combination travoprost 0.004%/timolol 0.5% in patients transitioning from bimatoprost 0.03%/timolol 0.5% combination therapyFixed-combination treatments for intraocular hypertension in Chinese patients - focus on bimatoprost-timolol.Intraocular pressure after replacement of current dual therapy with latanoprost monotherapy in patients with open angle glaucoma.Brinzolamide/timolol versus dorzolamide/timolol fixed combinations: A hospital-based, prospective, randomized studyFixed Combination of Travoprost and Timolol Maleate Reduces Intraocular Pressure in Japanese Patients with Primary Open-Angle Glaucoma or Ocular Hypertension: A Prospective Multicenter Open-Label Study.Fixed combination of travoprost and timolol maleate reduces intraocular pressure in Japanese patients with primary open-angle glaucoma or ocular hypertension: analysis by prostaglandin analogue.Six-month results from a Phase III randomized trial of fixed-combination brinzolamide 1% + brimonidine 0.2% versus brinzolamide or brimonidine monotherapy in glaucoma or ocular hypertension.Phase 3 randomized 3-month trial with an ongoing 3-month safety extension of fixed-combination brinzolamide 1%/brimonidine 0.2%.Travoprost/timolol fixed combination.A study of the safety and efficacy of travoprost 0.004%/timolol 0.5% ophthalmic solution compared to latanoprost 0.005% and timolol 0.5% dosed concomitantly in patients with open-angle glaucoma or ocular hypertensionDaily costs of prostaglandin analogues as monotherapy or in fixed combinations with timolol, in Denmark, Finland, Germany and SwedenPhase III safety and efficacy study of long-term brinzolamide/timolol fixed combination in Japanese patients with open-angle glaucoma or ocular hypertension.Efficacy and safety of brinzolamide/timolol fixed combination compared with timolol in Japanese patients with open-angle glaucoma or ocular hypertension.Role of fixed combinations in the management of open-angle glaucoma.Novel strategies for anterior segment ocular drug delivery.Contact lenses as a platform for ocular drug delivery.Fixed-combination intraocular pressure-lowering therapy for glaucoma and ocular hypertension: advantages in clinical practice.A review on therapeutic contact lenses for ocular drug delivery.Are contact lenses the solution for effective ophthalmic drug delivery?Ocular inserts - Advancement in therapy of eye diseases.Managing refractory glaucoma with a fixed combination of bimatoprost (0.03%) and timolol (0.5%).Safety and efficacy of a fixed versus unfixed brinzolamide/timolol combination in Japanese patients with open-angle glaucoma or ocular hypertension.Release of Moxifloxacin from Contact Lenses Using an In Vitro Eye Model: Impact of Artificial Tear Fluid Composition and Mechanical Rubbing.
P2860
Q26830201-35B04E18-CF24-42C0-82CA-8E99CE87434DQ28074316-EF4A38D0-CF2C-42BF-98C1-67EA94E2FCAEQ33307040-8CE01D1F-35EB-465F-A1EA-35C1BA97EF62Q33492367-3E721659-C786-4B25-9AB4-8A561A158CF1Q33650686-3C4B4EAE-CA43-4D8E-A6E7-8408074CDE34Q34090075-3043C1C1-80BC-4A83-9712-FC9DA65DC172Q34156665-10AE1424-08BB-456C-9964-F6437324B62BQ34188272-D4502A23-943F-41CB-A65C-277B5CBBC027Q34253481-74433E48-8ECC-45F5-A7B4-33F4AE914CD7Q34493789-C16AB84B-F6CC-4A2B-9ADA-7BF43AF1F088Q34512297-959DD0AF-352E-41BD-AD9B-909A7640B1AAQ34737217-32638619-AAB1-4908-8A58-D024DE7A7777Q34996623-525465C6-A83A-4113-A628-D61991823F03Q35104759-71AE38C7-CDC0-4D6E-8E19-371475404334Q35590154-17E7D772-8AD9-4B24-B7F4-87582AC92AD6Q35590848-BD565922-3BFB-40F2-80F9-3278DCD5B54EQ35592686-53F0376A-0019-4C94-9446-1F70176F03AAQ35596464-A61C67AB-46AA-4CEB-B94F-060C47974371Q35617544-ECC97C91-EAA4-4D92-82D3-81D982918323Q35894656-AD5DD5FA-D7C8-4616-8609-73B116AE8BEBQ35981031-8D3F4A43-DD9B-46C4-8F18-75F9DE0B7273Q36158856-700EDE5D-378B-433E-9D7E-E7D02EB23FD9Q36239886-19DF0198-9299-41B7-9512-D9E9F31A3BE3Q36919451-5B89034D-634D-4384-83C3-6BCA6597182CQ36968248-8A20B321-49CD-4998-A095-366487FD8225Q37123433-BEE4DDB0-33F8-447C-9232-B75F0876E3C3Q37221491-B8305D71-9100-469B-B0A4-417FDD706D75Q37318853-2FCFF2F7-D028-45F7-9AAE-07BFF65EA86DQ37444622-64A65055-6AE1-4957-964E-70CB6CC7711BQ37588447-40683172-1685-4F84-8EAC-7A0563BDDE5CQ37847155-99799F44-FDEF-444B-B073-BC56D9BF8B16Q38065184-139D247B-01FD-4405-B1DC-5A9B96C849CDQ38123230-362EAEAC-7157-45F7-998A-0366473F5130Q38226662-9366BE34-A916-4A2F-B6FE-1347DE42CD18Q38715163-81CC6A74-962D-4020-874A-3D77886A3FA7Q39512489-BA58CA7C-A2EE-4155-A42E-2F71E8765F70Q40303356-7DA80C2D-D8A7-4340-99EF-73491A7F5F91Q41352665-A46F35BE-2903-4223-BB3C-DFEC9394695DQ41877762-E1FA43BA-8066-4310-8B93-4D894D4B9466Q42369732-FBA9D8F7-9CDB-406C-9884-31BB771BA818
P2860
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
description
1974 nî lūn-bûn
@nan
1974年の論文
@ja
1974年学术文章
@wuu
1974年学术文章
@zh
1974年学术文章
@zh-cn
1974年学术文章
@zh-hans
1974年学术文章
@zh-my
1974年学术文章
@zh-sg
1974年學術文章
@yue
1974年學術文章
@zh-hant
name
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@en
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@nl
type
label
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@en
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@nl
prefLabel
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@en
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@nl
P2093
P356
P1476
Drop size and initial dosing frequency problems of topically applied ophthalmic drugs.
@en
P2093
P304
P356
10.1002/JPS.2600630304
P407
P577
1974-03-01T00:00:00Z